Clinical Trial Update: SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth [Phase 2]

View source ↗

Summary

SWOG-9507, a Phase 2 trial of fenretinide in patients with mouth neoplasia, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Cancer

Drugs mentioned

• Fenretinide (fenretinide)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Head and Neck Cancer | Phase 2 | Status: TERMINATED